Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of EP0057 in combination with olaparib in advanced ovarian cancer
2020-003083-98Phase 2Unknown
- Sponsor
- Ellipses Pharma
- Start
- Oct 2020
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of CRLX101 and olaparib in ovarian cancer (2 cohorts), sponsored by Ellipses Pharma. Status: unknown.
02
Drugs
CRLX101olaparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2020-003083-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003083-98.